
American Thoracic Society International Conference 2025 (ATS 2025)
San Francisco, California, US 16 May 2025 - 21 May 2025
First-line methotrexate on par with prednisone for sarcoidosis
18 Jun 2025
byStephen Padilla
The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.
First-line methotrexate on par with prednisone for sarcoidosis
18 Jun 2025
BGF initiation after an exacerbation in COPD: Does timing matter?
06 Jun 2025
byAudrey Abella
Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).
BGF initiation after an exacerbation in COPD: Does timing matter?
06 Jun 2025
WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma
03 Jun 2025
byAudrey Abella
Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.